The Hindu·2 min read·medium
India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease
T
The Hindu Bureau
✦AI Summary
The Central Drugs Standard Control Organization has approved Novo Nordisk's drug Wegovy for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). This marks the first time a GLP-1 receptor agonist has been approved in India for this specific liver condition.
The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication — fatty liver disease.
healthsciencebusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in